The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Subscribe To Our Newsletter & Stay Updated
